Journal
CANCER INVESTIGATION
Volume 31, Issue 3, Pages 197-205Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/07357907.2013.775294
Keywords
Adoptive immunotherapy; Non-small cell lung cancer; Clinical study; Influence factor
Categories
Funding
- National Basic Research Program of China (973 Program) [2012CB9333004]
- National High Technology Research and Development Program of China (863 Program) [SS2012AA020403]
Ask authors/readers for more resources
Non-small cell lung cancer (NSCLC) is found worldwide with high incidence and poor prognoses. Nowadays, insights in the interaction between tumors and immune system have led to the development of immunotherapy as a fundamentally new concept for the treatment of NSCLC. Adoptive cell transfer represents an important advancement in cancer immunotherapy such as cytokine-induced killer and gamma delta T-cells. Recent clinical research studies provide evidence for the positive effects of adoptive immunotherapy, which is probably associated with levels of cytokines, cell doses, and immune microenvironment. This review summarizes the current condition of adoptive immunotherapy in NSCLC and the long-standing confusion in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available